The Russian Direct Investment Fund (RDIF) continues negotiations with Turkish partners on joint production of the Sputnik V coronavirus vaccine, Russian Ambassador to Ankara Alexey Yerkhov said in an interview with RIA Novosti.
Earlier RIA Novosti was informed by the RDIF that the fund signed an agreement with a leading Turkish pharmaceutical manufacturer to produce the Russian vaccine against coronavirus Sputnik V in Turkey and started transferring the technology. Ozturk Oran, the chairman of the board of directors of the Turkish pharmaceutical company VisCoran, told RIA Novosti that Turkey intends to set up production of the Sputnik V coronavirus vaccine both for its own needs and for export.
"The RDIF has certain agreements with Turkish partners. However, we have to understand that every country - and Turkey is no exception - has its own legislation regulating the procedure of official registration of import and use of medical products, especially those made abroad. In our case, this is also important because we are working on the possibility of joint production of the Sputnik V vaccine in Turkey. So, the relevant work is underway, negotiations continue, follow the news," the agency's interlocutor said.
The use of the Sputnik V vaccine has previously been approved in 20 countries: Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua and Republic of Srpska (the entity of Bosnia and Herzegovina) and Lebanon.
GSV "Russia - Islamic World"
Photo: Andrey Luzik / TASS
Based on materials from RIA Novosti